RxDoctor Payments Data

Ronald Wilson, MD

Neurology · Brentwood, TNNPI 1497749568

Payments from drug & device makers

$29,631in general payments, 2019–2025

Across 405 payments — averaging $73.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Acadia Pharmaceuticals Inc$11K
  • Lilly USA, LLC$7K
  • Novartis$4K
  • Biogen$838
  • Amgen$790
  • Sanofi$541
  • plus $4K from 50 others

What the payments were for

  • Consulting fees$13,16944%
  • Speaking & faculty fees$6,74323%
  • Travel & lodging$1,9957%
  • Food & beverage$7,68726%
  • Education$380%

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Acadia Pharmaceuticals Inc31$11,358
Lilly USA, LLC21$7,218
Novartis11$4,461
Biogen34$838
Amgen(2 entities)32$790
Sanofi24$541
AbbVie(2 entities)27$447
EMD Serono, Inc.30$447
Sunovion Pharmaceuticals Inc.21$320
AstraZeneca(2 entities)15$271
Teva Pharmaceuticals USA, Inc.17$225
Neurocrine Biosciences, Inc.11$221
Johnson & Johnson13$206
UCB, Inc.8$175
Lundbeck LLC8$156
CSL Behring8$154
Kyowa Kirin, Inc.8$135
Avanir Pharmaceuticals, Inc.6$130
Boston Scientific6$119
Supernus Pharmaceuticals, Inc.7$114
Argenx US, Inc.3$90
E.r. Squibb & Sons, L.L.C.5$90
SK Life Science, Inc.4$88
Acorda Therapeutics, Inc4$84
Adamas Pharmaceuticals, Inc.4$72
Eisai Inc.4$66
Harmony Biosciences LLC2$66
Amneal Pharmaceuticals LLC4$62
Portola Pharmaceuticals, LLC3$57
Axsome Therapeutics, Inc.2$56
Jazz Pharmaceuticals Inc.3$54
Biohaven Pharmaceuticals, Inc.2$38
Vertical Pharmaceuticals, LLC2$36
Avion Pharmaceuticals2$35
Genentech USA, Inc.2$29
Sumitomo Pharma America, Inc.1$28
Medtronic1$25
Banner Life Sciences, LLC1$25
Mallinckrodt Hospital Products Inc.1$23
Livanova USA, Inc.1$22
GE HealthCare1$22
Biohaven Pharmaceutical Holding Company Ltd.1$20
Alnylam Pharmaceuticals Inc.1$18
Aquestive Therapeutics, Inc.1$18
Merz North America, Inc.1$17
TG Therapeutics, Inc.1$17
Greenwich Biosciences, Inc.1$17
Neurelis, Inc.1$17
Takeda Pharmaceuticals U.S.A., Inc.1$15
Aprecia Pharmaceuticals, LLC1$15
Idorsia Pharmaceuticals US Inc1$15
Kedrion Biopharma Inc.1$14
Tanabe Pharma America, Inc.1$14
Xeris Pharmaceuticals, Inc.1$14
Bristol Myers Squibb1$13
MDD US Operations, LLC1$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$29,631 in reported general payments places this provider in the 75th percentile of 361 neurology providers in Tennessee.

See all neurology providers in Tennessee

Medicare billing

Part B allowed, 2024
$38,206
Medicare patients
121
Services billed
2,115

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trokendi XrTopiramate16$7,372
Levetiracetam30$917
Carbidopa-LevodopaCarbidopa/Levodopa23$803
Primidone13$484
Gabapentin14$448
Pramipexole DihydrochloridePramipexole Di-Hcl20$261
Donepezil Hcl12$185
Sertraline Hcl12$152

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Supernus Pharmaceuticals, Inc.Trokendi Xr$114$7,37216 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 361 neurology providers in Tennessee.

Other neurology in Brentwood

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →